Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd, filed a Form 144 notice on November 12, 2026, proposing the sale of 44,710 ordinary shares acquired through a stock option exercise and sale on the same date.

Key Highlights

  • Seller: Mark Sabag, identified in the filing as an officer with the title Executive VP International Markets Commercial.
  • Shares proposed for sale: 44,710 ordinary shares, with an aggregate market value of $1,973,545.81, based on an indicative market price of $44.141038 per share.
  • Nature of acquisition: The securities were acquired on November 12, 2026, through a stock option exercise and sale, with payment classified as compensation.
  • Broker: Citigroup Global Markets Inc., 390 Greenwich Street, New York, NY 10013, is named as the broker for the proposed sale on NYSE.
  • Prior sales: Sabag also sold 46,000 ordinary shares on November 5, 2026, with gross proceeds of $1,928,728.30, according to the three-month sales history section of the filing.
  • Shares outstanding: The filing states 1,166,826,784 ordinary shares outstanding at the time of notice.

Sabag's Proposed Ordinary Share Sale at Teva Pharmaceutical

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Mark Sabag, an officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), is proposing to sell 44,710 ordinary shares. The filing reports the aggregate market value of those shares as $1,973,545.81, calculated using an indicative market price of $44.141038 per share. The shares were acquired on November 12, 2026, through a stock option exercise and sale, with the nature of payment listed as compensation.

The filing discloses that the proposed sale is to be executed on the NYSE on November 12, 2026, through Citigroup Global Markets Inc. The Form 144 also requires disclosure of sales made in the prior three months: Sabag sold 46,000 ordinary shares on November 5, 2026, generating gross proceeds of $1,928,728.30. The combined activity reflects two separate transactions within a short window.

The filing notes that the shares outstanding figure is based on ordinary shares, and that the aggregate market value is based on an indicative market price. The filer's remarks section states: "SECTION 3 D BASED ON INDICATIVE MARKET PRICE 44.141038. SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES." Teva Pharmaceutical Industries Ltd is headquartered at 124 Dvora HaNevi'a St., Tel Aviv, Israel.

What Was Disclosed

Mark Sabag, an executive officer at Teva Pharmaceutical Industries Ltd, filed a Form 144 on November 12, 2026, notifying the SEC of a proposed sale of 44,710 ordinary shares acquired through a stock option exercise, with an aggregate market value of $1,973,545.81.